Literature DB >> 1363103

Genetic and immunologic analysis of a family containing five patients with common-variable immune deficiency or selective IgA deficiency.

R F Ashman1, F M Schaffer, J D Kemp, W M Yokoyama, Z B Zhu, M D Cooper, J E Volanakis.   

Abstract

A family with 13 members included 2 subjects with selective IgA deficiency (IgA-D) and 3 subjects with common-variable immune deficiency (CVID), diseases which usually occur sporadically. Reciprocal combinations of B and T cells in vitro between one normal and two immune-deficient family members and normal subjects revealed that defective Ig synthesis was determined by the B cells, while the patient T cells functioned normally. Normal T helper and suppressor function was demonstrated even in one patient with CVID who developed a T-cell lymphoproliferative disorder associated with elevated IgM; this patient's B cells made only IgM in vitro. Immune deficiencies were inherited in this family in a pattern consistent with an autosomal dominant trait with incomplete penetrance. All the immune-deficient patients in this family possessed at least one copy of an MHC haplotype previously shown to be abnormally frequent in IgA-D and CVID: HLA-DQB1*0201, HLA-DR3, C4B-Sf, C4A-deleted, G11-15, Bf-0.4, C2-a, HSP70-7.5, TNF alpha-5, HLA-B8, and HLA-A1. The patient who developed the lymphoproliferative disorder was homozygous for this haplotype. Four immunologically normal members, one of whom was 80 years old, also possessed this MHC haplotype, indicating that its presence is not sufficient for disease expression. A small segment of another MHC haplotype associated with Ig deficiency in the population also occurred in this family, but it was not associated with immune deficiency.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363103     DOI: 10.1007/bf00918852

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  37 in total

1.  PRIMARY "ACQUIRED" HYPOGAMMAGLOBULINEMIA; CLINICAL AND GENETIC ASPECTS OF NINE CASES.

Authors:  F A WOLLHEIM; S BELFRAGE; C COESTER; H LINDHOLM
Journal:  Acta Med Scand       Date:  1964-07

2.  Regulation of immunoglobulin production in human peripheral bood leukocytes: cellular interactions.

Authors:  A Saxon; R H Stevens; R F Ashman
Journal:  J Immunol       Date:  1977-05       Impact factor: 5.422

3.  Abnormalities of lymphokine gene expression in patients with common variable immunodeficiency.

Authors:  M C Sneller; W Strober
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  DNA in heritable disease.

Authors:  B C Sykes
Journal:  Lancet       Date:  1983-10-01       Impact factor: 79.321

6.  Rapid separation of human monocytes and lymphocytes by Sephadex G-10.

Authors:  M M Chien; R F Ashman
Journal:  J Immunol Methods       Date:  1984-06-08       Impact factor: 2.303

7.  Suppression of B-cell differentiation by leukocytes from hypogammaglobulinemic patients.

Authors:  F P Siegal; M Siegal; R A Good
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

8.  Major histocompatibility complex class III genes and susceptibility to immunoglobulin A deficiency and common variable immunodeficiency.

Authors:  J E Volanakis; Z B Zhu; F M Schaffer; K J Macon; J Palermos; B O Barger; R Go; R D Campbell; H W Schroeder; M D Cooper
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

9.  Aspartic acid at position 57 of the HLA-DQ beta chain protects against type I diabetes: a family study.

Authors:  P A Morel; J S Dorman; J A Todd; H O McDevitt; M Trucco
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

10.  Profile of multiple lymphocyte functional defects in acquired hypogrammaglobulinemia, derived from in vitro cell recombination analysis.

Authors:  R F Ashman; A Saxon; R H Stevens
Journal:  J Allergy Clin Immunol       Date:  1980-04       Impact factor: 10.793

View more
  6 in total

1.  IgA deficiency and the MHC: assessment of relative risk and microheterogeneity within the HLA A1 B8, DR3 (8.1) haplotype.

Authors:  Javad Mohammadi; Ryan Ramanujam; Sara Jarefors; Nima Rezaei; Asghar Aghamohammadi; Peter K Gregersen; Lennart Hammarström
Journal:  J Clin Immunol       Date:  2009-10-16       Impact factor: 8.317

2.  Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes.

Authors:  H W Schroeder; Z B Zhu; R E March; R D Campbell; S M Berney; S A Nedospasov; R L Turetskaya; T P Atkinson; R C Go; M D Cooper; J E Volanakis
Journal:  Mol Med       Date:  1998-02       Impact factor: 6.354

Review 3.  TACI mutation in common variable immunodeficiency and IgA deficiency.

Authors:  Rima Rachid; Emanuela Castigli; Raif S Geha; Francisco A Bonilla
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

4.  HLA class II homozygosity confers susceptibility to common variable immunodeficiency (CVID).

Authors:  E G De La Concha; M Fernandez-Arquero; A Martinez; F Vidal; P Vigil; L Conejero; M C Garcia-Rodriguez; G Fontan
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

5.  Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry.

Authors:  H Kanegane; S Tsukada; T Iwata; T Futatani; K Nomura; J Yamamoto; T Yoshida; K Agematsu; A Komiyama; T Miyawaki
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

6.  Linkage of autosomal dominant common variable immunodeficiency to chromosome 5p and evidence for locus heterogeneity.

Authors:  D U Braig; A A Schäffer; E Glocker; U Salzer; K Warnatz; H H Peter; B Grimbacher
Journal:  Hum Genet       Date:  2003-02-06       Impact factor: 4.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.